Skip to main content
SpringerLink
Log in

Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration

  • Brief Report
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Although cyclosporine (CsA) therapy is effective in the management of children with steroid-dependent nephrotic syndrome (SDNS), a recent study has revealed that the use of CsA itself was a significant predictor of NS relapse in adulthood. The efficacy of single daily high-dose mizoribine (MZR) therapy was assessed in 10 children with SDNS (mean age, 6.2 years) who had never been treated with CsA previously. MZR was started at 5 mg/kg, administered as a single daily dose after breakfast, and the dose was adjusted to achieve 2-h post-dose MZR levels (C2) of approximately 3 μg/ml. In 9 of the 10 patients, treatment with a single daily dose of MZR (mean dose, 8.4 mg/kg/day) over a period of 22 months (median) resulted in significant reduction of the mean prednisolone dose from 0.39 to 0.15 mg/kg/day and the median 12-month relapse rate from 3.0 to 0.4 episodes/12 months. Although cyclophosphamide was initiated in one patient because of treatment failure, none of the 10 patients required treatment with CsA during the observation period (median, 33 months). These data indicate that single daily high-dose MZR therapy is possibly useful in treating children with SDNS and that it may also eliminate the need for CsA in some patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hodson EM, Alexander SI (2008) Evaluation and management of steroid-sensitive nephrotic syndrome. Curr Opin Pediatr 20:145–150

    Article  PubMed  Google Scholar 

  2. Trompeter RS, Lloyd BW, Hicks J, White RH, Cameron JS (1985) Long-term outcome for children with minimal-change nephrotic syndrome. Lancet 16:368–370

    Article  Google Scholar 

  3. Lewis MA, Baildom EM, Davis N, Houston IB, Postlethwaite RJ (1989) Nephrotic syndrome: from toddlers to twenties. Lancet 4:255–259

    Article  Google Scholar 

  4. Lahdenkari AT, Suvanto M, Kajantie E, Koskimies O, Kestilä M, Jalanko H (2005) Clinical features and outcome of childhood minimal change nephrotic syndrome: is genetics involved? Pediatr Nephrol 20:1073–1080

    Article  PubMed  Google Scholar 

  5. Fakhouri F, Bocquet N, Taupin P, Presne C, Gagnadoux MF, Landais P, Lesavre P, Chauveau D, Knebelmann B, Broyer M, Grünfeld JP, Niaudet P (2003) Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis 41:550–557

    Article  PubMed  Google Scholar 

  6. Rüth EM, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ (2005) Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr 147:202–207

    Article  PubMed  Google Scholar 

  7. Kyrieleis HA, Löwik MM, Pronk I, Cruysberg HR, Kremer JA, Oyen WJ, van den Heuvel BL, Wetzels JF, Levtchenko EN (2009) Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol 4:1593–1600

    Article  PubMed  Google Scholar 

  8. Ohtom Y, Fujinaga S, Takada M, Murakami H, Akashi S, Shimizu T, Kaneko K, Yamashiro Y (2005) High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity. Pediatr Nephrol 20:1744–1749

    Article  Google Scholar 

  9. Komiya H, Masubuchi Y, Mori Y, Tajima N (2008) The validity of body mass index criteria in obese school-age children. Tohoku J Exp Med 214:27–37

    Article  PubMed  Google Scholar 

  10. Kemper MJ, Kuwertz-Broeking E, Bulla M, Mueller-Wiefel DE, Neuhaus TJ (2004) Recurrence of severe steroid dependency in cyclosporin A-treated childhood idiopathic nephrotic syndrome. Nephrol Dial Transplant 19:1136–1141

    Article  PubMed  CAS  Google Scholar 

  11. Fujinaga S, Kaneko K, Muto T, Ohtomo Y, Murakami H, Yamashiro Y (2006) Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome. Arch Dis Child 91:666–670

    Article  PubMed  CAS  Google Scholar 

  12. Okada M, Sugimoto K, Yagi K, Yanagida H, Tabata N, Takemura T (2007) Mycophenolate mofetil therapy for children with intractable nephrotic syndrome. Pediatr Int 49:933–937

    Article  PubMed  CAS  Google Scholar 

  13. Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H (2000) Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun 274:87–92

    Article  PubMed  CAS  Google Scholar 

  14. Hulton S-A, Neuhaus TJ, Dillon MJ, Barratt TM (1994) Long-term cyclosporine A treatment of minimal change nephrotic syndrome of childhood. Pediatr Nephrol 8:401–403

    Article  PubMed  CAS  Google Scholar 

  15. Kawasaki Y, Takano K, Isome M, Suzuki J, Suyama K, Kanno H, Fujiki T, Suzuki H, Hosoya M (2007) Efficacy of single dose of oral mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome. J Nephrol 20:52–56

    PubMed  CAS  Google Scholar 

  16. Kawasaki Y, Suzuki J, Takahashi A, Isome M, Nozawa R, Suzuki H (2005) Mizoribine oral pulse therapy for steroid-dependent nephrotic syndrome. Pediatr Nephrol 20:96–98

    Article  PubMed  Google Scholar 

  17. Fujieda M, Ishihara M, Morita T, Hayashi A, Utsunomiya Y, Ohta T, Sakano T, Wakiguchi H (2008) Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome. Clin Nephrol 69:179–184

    PubMed  CAS  Google Scholar 

Download references

Acknowledgement

The authors thank Asahi-Kasei Pharma Co. Ltd. (Tokyo) for the measurement of MZR blood levels.

Author information

Authors and Affiliations

  1. Division of Nephrology, Saitama Children’s Medical Center, 2100 Magome, Iwatsuki-ward, Saitama-city, Saitama, 339 8551, Japan

    Shuichiro Fujinaga, Daishi Hirano & Naoto Nishizaki

  2. Department of Pediatrics, Juntendo University School of Medicine, Tokyo, Japan

    Tomonosuke Someya, Yoshikazu Ohtsuka & Toshiaki Shimizu

  3. Department of Pediatrics, Juntendo Nerima Hospital, Tokyo, Japan

    Yoshiyuki Ohtomo

  4. Department of Pediatrics, Kansai Medical University, Osaka, Japan

    Kazunari Kaneko

Authors
  1. Shuichiro Fujinaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daishi Hirano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naoto Nishizaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomonosuke Someya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshiyuki Ohtomo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshikazu Ohtsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toshiaki Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazunari Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuichiro Fujinaga.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fujinaga, S., Hirano, D., Nishizaki, N. et al. Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration. Pediatr Nephrol 26, 479–483 (2011). https://doi.org/10.1007/s00467-010-1707-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-010-1707-7

Keywords

Search

Navigation